hVIVO (LON:HVO) Releases Quarterly Earnings Results

hVIVO (LON:HVO) posted its earnings results on Tuesday. The company reported GBX (0.82) earnings per share (EPS) for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Trading Down 3.3%

Shares of hVIVO stock traded down GBX 0.20 during midday trading on Wednesday, reaching GBX 5.90. 2,205,686 shares of the company’s stock traded hands, compared to its average volume of 2,550,895. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. The company has a market cap of £40.62 million, a PE ratio of -6.78 and a beta of 1.69. The stock has a 50 day moving average of GBX 6.81 and a 200-day moving average of GBX 7.41. hVIVO has a 12 month low of GBX 4.30 and a 12 month high of GBX 11.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.